Organization
Centre Georges Francois Leclerc
17 clinical trials
4 abstracts
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.Org: Institut de Cancerologie de l'Ouest, ICO Institut de Cancerologie de l'Ouest, Institut de Cancérologie de l'Ouest, Centre Antoine Lacassagne, Centre Georges Francois Leclerc,
Clinical trial
Phase II Multicentric, Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXELStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset CancerStatus: Recruiting, Estimated PCD: 2026-10-07
Abstract
Optimization of surgical management of the axilla since MonarchE trial.Org: Georges François Leclerc Comprehensive Cancer Care Centre, Centre Georges François Leclerc, Centre Georges Francois Leclerc,
Clinical trial
Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib TreatmentStatus: Active (not recruiting), Estimated PCD: 2027-08-10
Clinical trial
Phase Ib/II Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.Status: Not yet recruiting, Estimated PCD: 2029-04-01
Clinical trial
Study of Exosomes in Monitoring Patients With Sarcoma (EXOSARC)Status: Recruiting, Estimated PCD: 2024-11-19
Clinical trial
Phase II Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy (FOLFIRINOX3 Pancréas)Status: Recruiting, Estimated PCD: 2029-07-24
Clinical trial
Phase II Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Vascularization of Liver Metastases of Metastatic Colorectal Cancer: Proof of Concept StudyStatus: Completed, Estimated PCD: 2014-10-10
Clinical trial
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP InhibitorsStatus: Active (not recruiting), Estimated PCD: 2022-11-10
Clinical trial
Validation of a Genetic Signature to Predict the Development of SarcomasStatus: Completed, Estimated PCD: 2022-06-19
Clinical trial
Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile LesionsStatus: Recruiting, Estimated PCD: 2025-09-27
Clinical trial
A Multicenter, Prospective, Multi-organ Study to Evaluate the Clinical Benefit of an Exome "Complex" Analysis Versus an Exome "Simple" Analysis to Help the Therapeutic Decision for the Precision MedicineStatus: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
An Open-label, Multi-centric, Phase I, Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)Status: Recruiting, Estimated PCD: 2024-12-05
Clinical trial
Study of Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response Between 1 and 3 Months After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer CenterStatus: Completed, Estimated PCD: 2022-01-26
Clinical trial
Phase I / II Study Evaluating the Efficacy and Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer Who Have Failed With Standard Chemotherapy Protocols (FOLFIRINOX 3)Status: Active (not recruiting), Estimated PCD: 2024-11-21
Clinical trial
Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide RegenerationStatus: Recruiting, Estimated PCD: 2025-09-02
Clinical trial
Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, FluoropyrimidineStatus: Recruiting, Estimated PCD: 2026-10-13
Clinical trial
Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2023-01-09
Abstract
CD47 expression in ovarian cancer: Dynamic correlation with lymphocyte and macrophage features as well as thrombospondin-1 (TSP-1) under neoadjuvant chemotherapy.Org: Gustave Roussy Cancer Center, INSERM U981 GUSTAVE ROUSSY, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), CNRS UMR 7369 MEDyC - Reims University, Apmonia Therapeutics,
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.Org: Institut de Cancerologie de l'Ouest, Saint-Herblain, France, Gustave Roussy Cancer Center, ICO Institut de Cancerologie de l'Ouest, Oscar Lambret Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France,